Analgesia and supportive care
›Symptom control bundle
›Non-opioid analgesia
›Ibuprofen PO 400 mg
›Frequency every 6 to 8 hours as needed
›Maximum 2400 mg per day typical
›Avoid in significant renal disease or active GI bleeding risk
›Acetaminophen PO 1000 mg
›Frequency every 6 hours as needed
›Maximum 3000 mg per day typical
›Lower maximum with chronic liver disease or heavy alcohol use
›Opioid sparing escalation when severe pain
›Short course opioid option if NSAID and acetaminophen inadequate
›Lowest effective dose
›Duration 1 to 3 days typical
›Avoid combined acetaminophen products if already using acetaminophen
›Hydration
›Oral fluids if tolerated
›IV crystalloids if poor intake or sepsis physiology
›Indications for antibiotics
›Systemic involvement
›Fever
›Malaise
›Lymphadenopathy with cellulitis
›Spreading cellulitis
›Immunocompromised host
›Inability to obtain prompt dental source control
›Antibiotics not routinely indicated
›Localized dental pain without swelling and without systemic signs
›Definitive dental source control immediately available for localized abscess without systemic signs
›First-line oral regimens for uncomplicated infection
›Amoxicillin-clavulanate PO 875 mg
›Frequency twice daily
›Duration 5 to 7 days typical with reassessment
›Coverage for oral aerobes and anaerobes
›Penicillin VK PO 500 mg
›Frequency four times daily
›Pairing with metronidazole for anaerobe coverage when needed
›Duration 5 to 7 days typical
›Metronidazole PO 500 mg
›Frequency three times daily
›Use with penicillin when anaerobe coverage needed
›Avoid alcohol due to disulfiram-like reaction risk
›Penicillin allergy regimens
›Clindamycin PO 300 mg
›Frequency four times daily
›Duration 5 to 7 days typical
›C difficile risk counseling
›IV regimens for complicated infection or inability to take PO
›Ampicillin-sulbactam IV 3 g
›Frequency every 6 hours
›Transition to oral when clinically improved
›Renal dosing adjustments
›Ceftriaxone IV 2 g
›Frequency once daily
›Pairing with metronidazole for anaerobes
›Metronidazole IV 500 mg
›Frequency every 8 hours
›Transition to oral when tolerated
›Piperacillin-tazobactam IV 4.5 g
›Frequency every 6 to 8 hours
›Use for severe infection or broader coverage need
›Renal dosing adjustments
›MRSA coverage considerations
›Add vancomycin IV for severe infection with MRSA risk factors
›Initial dosing 15 to 20 mg per kg
›Frequency based on renal function and trough or AUC monitoring protocols
›Infusion rate considerations for infusion reaction
›Duration principles
›Short course with reassessment when source control achieved
›Longer course only if ongoing infection without definitive dental source control
Source control and procedures
›Dental source control hierarchy
›Definitive therapy
›Extraction of offending tooth
›Endodontic therapy when feasible
›ED temporizing options when appropriate expertise available
›Incision and drainage of fluctuant vestibular abscess
›Anesthesia with local infiltration or nerve block
›Blunt dissection and irrigation
›Culture only if immunocompromised or recurrent or severe
›Needle aspiration for superficial collection
›Ultrasound guidance when helpful
›Avoid deep space aspiration without specialty support
›Regional anesthesia options
›Inferior alveolar nerve block
›Useful for mandibular tooth pain
›Aspiration prior to injection to reduce intravascular risk
›Infraorbital nerve block
›Useful for maxillary anterior pain
›Procedure contraindications and cautions
›Deep neck space concern requiring operative management
›Coagulopathy with uncontrolled bleeding risk
›Airway compromise requiring higher level setting
Airway and severe infection management
›Ludwig angina or deep space infection bundle
›Early airway planning
›Awake technique consideration
›Backup surgical airway planning with ENT
›Broad spectrum IV antibiotics
›Ampicillin-sulbactam or piperacillin-tazobactam
›Add MRSA coverage if risk factors or severe sepsis
›Imaging support
›CT neck with IV contrast when stable for transport
›ICU monitoring triggers
›Airway risk signs
›Rapid progression
›Sepsis physiology